IGI Logo

Strides Pharma Science is currently trading at Rs. 813.45, up by 4.85 points or 0.60% from its previous closing of Rs. 808.60 on the BSE.

The scrip opened at Rs. 809.90 and has touched a high and low of Rs. 818.10 and Rs. 807.40 respectively. So far 2562 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 838.10 on 20-Feb-2024 and a 52 week low of Rs. 268.40 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 834.00 and Rs. 770.85 respectively. The current market cap of the company is Rs. 7431.01 crore.

The promoters holding in the company stood at 27.39%, while Institutions and Non-Institutions held 38.86% and 33.75% respectively.

Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global, Singapore, has received approval for Gabapentin Tablets USP, 600 mg and 800 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC.  
Gabapentin tablets has a market size of around $140 million as per IMS. This approval further strengthens the Company's presence in the Gabapentin portfolio, complementing the existing approval of Gabapentin capsules, which has a market size of $208 million. The Gabapentin tablets will be manufactured at the company’s facility in Puducherry.

The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 235+ ANDAs have been approved. The company has set a target to launch around 60 new products over three years in the US.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.